Request DRA’s expertise to guide you through the Fimea COHERE procedures needed for hospital access for new hospital-only pharmaceuticals in Finland. We can compile documentation and localise assessments for you, and also communicate with the authorities on your behalf. In addition, we support you with hospital tenders for your hospital-only pharmaceutical products throughout the whole process from submitting tenders to following up decisions.
Our hospital access and hospital tender services for hospital-only pharmaceuticals include:
- Compiling and submitting documents and agreements
- Localising clinical assessments and health economic assessments
- Discussing with Fimea during the assessment process
- Monitoring for new tenders
- Translations of tenders, hospital pharmacy requirements and supporting documentation
Request DRA’s expertise to guide you through the Fimea COHERE procedures that are required to obtain hospital access for new hospital-only pharmaceutical products. In the Finnish market, the assessment and application procedures for obtaining hospital access are different from those for open care. The (Finnish Medicines Agency) Fimea and the Council for Choices in Health Care in Finland (COHERE Finland) handle the health economic assessments of hospital-only medicinal products. To gain hospital access, a new medicine first requires an Assessment Report from Fimea and then a National Recommendation from COHERE. After this, hospitals can access and procure the drug.
Also ask for DRA’s support with hospital tenders for your hospital-only pharmaceutical products. When hospitals procure pharmaceuticals and medical devices they must publish a public tender, as required by law. DRA can support your company’s business at all phases of the tender process, from identifying new tenders and informing your company of the opportunity, to translating all documentation required by the hospital pharmacists and submitting the tender documentation.
DRA Consulting is now PharmaLex Finland
As we are merging with the global service provider PharmaLex, our name has been changed to PharmaLex Finland.
Biological medicines: how does their manufacturing process differ from traditional medicines?
The differences in the manufacturing process and the nature of the active substance itself mean that biologicals differ from traditional medicines in many ways.